ClinicalTrials.gg
CompletedNCT07246291Updated Sep 30, 2026

Comparative Study of EnliTuo® Before and After Technology Change in Healthy Male Volunteers

A Phase 1 interventional study of New technology Enlituo and Approved technology Enlituo in Healthy Adult Male, sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd · Phase 1, Interventional, and Treatment

How we know

Updated Sep 30, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study is a randomized, double-Blind, parallel-controlled, single-dose pharmacokinetic, safety, and immunogenicity comparative study of EnliTuo® before and after technology change in healthy male volunteers.

02

Conditions studied

  • Healthy Adult Male

Keywords

  • phrase 1
03

In context

Lead sponsor

Taizhou Mabtech Pharmaceutical Co.,Ltd is the lead sponsor of 18 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males aged ≥ 18 years and ≤ 45 years on the day of signing the form;
  • At screening, body weight ≥ 50 kg and ≤ 80 kg, with a (BMI) between 19.0 and 26.0 kg/m² (inclusive of boundary values);
  • Capable of understanding the study, including its purpose, research procedures, potential risks, etc., and able to communicate well with researchers and complete the study in accordance with the study requirements;
  • Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Subjects with any abnormally findings in comprehensive examinations (vital signs, physical examination, , chest X-ray, abdominal ultrasound, blood routine, urine routine, blood biochemistry, coagulation, etc.) as judged by the investigator;
  • Subjects with a history of major diseases in the cardiovascular, endocrine, nervous, digestive, respiratory, genitourinary, hematological, immune, or mental systems, or currently suffering from any disease in the above systems;
  • Subjects with a known or suspected history of keratitis, ulcerative keratitis, conjunctivitis, blepharitis, or severe dry eye;
  • Subjects with hereditary bleeding tendency, coagulation dysfunction, or a history of thrombotic or hemorrhagic diseases;
  • Subjects with active infections requiring systemic treatment;
  • Subjects positive for any of surface antigen, antibody, antibody, or Treponema pallidum antibody;
  • Subjects with a history of malignant tumors within the past 5 years, except for completely resected in-situ cutaneous basal cell carcinoma or squamous cell carcinoma;
  • Subjects who have undergone surgical operations within 4 weeks before screening, or plan to undergo surgery during the trial period;
  • Subjects who have used any prescription drugs, over-the-counter drugs, traditional Chinese medicines, proprietary Chinese medicines, health supplements, etc., within 4 weeks before screening, or whose use of the above substances has not exceeded 5 half-lives (whichever is longer);
  • Subjects who have used any biological products or received any vaccines within 12 weeks before screening, or plan to receive any vaccines during the study period;
  • Subjects currently enrolled in other clinical studies of drugs or medical devices, or whose time since the end of the last enrolled clinical study is less than 12 weeks, or whose time since the last trial drug administration has not exceeded 5 half-lives (whichever is longer);
  • Subjects positive for anti-drug antibodies against anti-epidermal growth factor receptor antibodies;
  • Subjects with substance abuse, or who have used soft drugs within 3 months before screening or hard drugs within 1 year before screening; or who consume excessive tea, coffee, and/or caffeinated beverages daily (more than 8 cups, 1 cup = 250 mL); or who have a positive urine drug screen;
  • Subjects with alcoholism, or whose weekly alcohol consumption exceeds 14 units within 3 months before screening (1 unit = 17.7 mL ethanol, i.e., 1 unit = 357 mL of beer with 5% alcohol content, 43 mL of liquor with 40% alcohol content, or 147 mL of wine with 12% alcohol content); or who have a positive alcohol breath test; and those who cannot cooperate with alcohol prohibition during the study;
  • Subjects who smoked more than 10 cigarettes per day on average within 6 months before screening;
  • Subjects who engaged in strenuous activities within 72 hours before drug administration, or cannot avoid strenuous activities during the study; or have other physiological or pathological conditions that may affect the absorption, distribution, metabolism, or excretion of the study drug;
  • Subjects who have donated blood (including component blood) or lost more than 400 mL of blood, or received blood transfusions within 3 months before screening; or donated blood (including component blood) or lost more than 200 mL of blood within 1 month before screening;
  • Subjects with a known history of allergy to the active ingredient or any of the study drug, or to other biological products; or with a history of atopic allergic diseases (e.g., asthma, urticaria, eczematous dermatitis, etc.); or with allergic diathesis;
  • Subjects who cannot tolerate venipuncture or have a history of fainting due to needle or blood;
  • Subjects with special dietary requirements who cannot accept the diet provided by the clinical trial center;
  • Subjects who cannot take effective measures or plan to donate sperm within 3 months after the administration of the study drug;
  • Other conditions deemed by the investigator to make the subject unsuitable for participating in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    New technology Enlituo

    treated with new technology Enlituo through single intravenous drip

    Biological: New technology Enlituo

  • Active comparator
    Approved technology Enlituo

    treated with Approved technology Enlituo through single intravenous drip

    Biological: Approved technology Enlituo

Interventions

  • BiologicalNew technology Enlituo

    250 mg/m\^2, single intravenous drip

  • BiologicalApproved technology Enlituo

    250 mg/m\^2, single intravenous drip

06

What researchers measure

Primary outcomes

  1. AUC0-∞

    Area under the concentration time curve extrapolated to infinity

    Time frame: From enrollment to the end of treatment at 28 days

Secondary outcomes

  1. AUC0-t

    Area under the concentration time curve from time zero to the last measurable time point.

    Time frame: From enrollment to the end of treatment at 28 days

  2. Cmax

    Peak concentration.

    Time frame: From enrollment to the end of treatment at 28 days

  3. Tmax

    time to peak

    Time frame: From enrollment to the end of treatment at 28 days

  4. t1/2

    half-life

    Time frame: From enrollment to the end of treatment at 28 days

  5. λz

    Terminal Elimination Rate Constant

    Time frame: From enrollment to the end of treatment at 28 days

  6. CL

    clearance

    Time frame: From enrollment to the end of treatment at 28 days

  7. Vd

    volume of distribution

    Time frame: From enrollment to the end of treatment at 28 days

  8. Immunogenicity

    Anti-drug antibody positive rate

    Time frame: From enrollment to the end of treatment at 28 days

  9. Adverse Event

    Incidence and Severity of Adverse Events

    Time frame: From enrollment to the end of treatment at 6 months

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: Yes — After the study result is published, email the application registration contact or the study leader to obtain it.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2025 to primary completion in Apr 2026, 5 months.

Completion moved once since we started tracking on Sep 25, 2026: May 2026 → Apr 2026, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 24, 2025
StartActual
Nov 11, 2025
Primary completionActual
Apr 14, 2026
CompletionActual
Apr 14, 2026was May 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 30, 2026
Primary completion
Apr 16, 2026→Apr 14, 2026
Sep 30, 2026
Study completion
May 13, 2026→Apr 14, 2026 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Active, not recruiting→Completed
    Primary completion Apr 16, 2026→Apr 14, 2026
    Study completion May 13, 2026→Apr 14, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07246291
Lead sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Nov 11, 2025
Primary completion
Apr 14, 2026
Completion
Apr 14, 2026
Last update
Sep 30, 2026

Study contacts

Jingying Jia, PhD
principal investigator · Xuhui Central Hospital, Shanghai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion